20.93

4.98% -0.9653

Dianthus Therapeutics Inc (DNTH)

Overview News Price History Financials Discussions Forecast

Dianthus Therapeutics Inc stock is traded at $20.93, with a volume of 55,687. It is down -4.98% in the last 24 hours and down -13.76% over the past month. Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Previous Close:

$21.90

Open:

$21.82

24h Volume:

55,687

Relative Volume:

0.25

Market Cap:

$671.09M

Revenue:

$4.12M

Net Income/Loss:

$-56.68M

P/E Ratio:

-3.7768

EPS:

-5.5429

Net Cash Flow:

$-51.44M

1W Performance:

-11.52%

1M Performance:

-13.76%

6M Performance:

-28.14%

1Y Performance:

-28.98%

1-Day Range:

$20.63

$22.16

1-Week Range:

$20.63

$24.80

52-Week Range:

$18.34

$33.77

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name

Dianthus Therapeutics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

929-999-4055

Address

7 TIMES SQUARE, NEW YORK

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

DNTH's Discussions on Twitter

Compare DNTH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNTH Dianthus Therapeutics Inc	20.81	671.09M	4.12M	-56.68M	-51.44M	-5.5429
VRTX Vertex Pharmaceuticals Inc	500.77	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.11	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.80	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.63	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.04	26.76B	3.32B	-860.46M	-1.04B	-8.32

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-26-24	Initiated	Robert W. Baird	Outperform
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy
Feb-15-24	Initiated	Stifel	Buy
Dec-26-23	Initiated	Jefferies	Buy
Nov-22-23	Initiated	Wedbush	Outperform
Oct-30-23	Initiated	Guggenheim	Buy
Sep-28-23	Initiated	Raymond James	Outperform
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-06-22	Upgrade	Goldman	Neutral → Buy
Aug-20-21	Resumed	Goldman	Neutral
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-21	Reiterated	B. Riley Securities	Buy
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight
Jun-15-21	Initiated	BTIG Research	Buy
May-18-21	Initiated	B. Riley Securities	Buy
Jan-07-21	Initiated	Mizuho	Buy
Jun-08-20	Upgrade	Goldman	Neutral → Buy
Mar-25-19	Downgrade	Goldman	Buy → Neutral
Mar-15-19	Initiated	Raymond James	Outperform

View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

10:44 AM

Wedbush Reaffirms Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat

10:44 AM

10:15 AM

Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat

10:15 AM

08:14 AM

Dianthus Therapeutics' (DNTH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

08:14 AM

06:44 AM

Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

06:44 AM

02:13 AM

Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World

02:13 AM

12:21 PM

Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks

12:21 PM

Mar 12, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

Mar 12, 2025

Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada

Mar 12, 2025

Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India

Mar 12, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5%Time to Sell? - MarketBeat

Mar 12, 2025

Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks

Mar 12, 2025

Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks

Mar 12, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages - Defense World

Mar 12, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Mar 12, 2025

Mar 11, 2025